{
    "clinical_study": {
        "@rank": "20160", 
        "arm_group": [
            {
                "arm_group_label": "Sarpogrelate pretreatment and Metoprolol", 
                "arm_group_type": "Experimental", 
                "description": "Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days and Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day"
            }, 
            {
                "arm_group_label": "Sarpogrelate and Metoprolol", 
                "arm_group_type": "Active Comparator", 
                "description": "Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day"
            }, 
            {
                "arm_group_label": "Metoprolol only", 
                "arm_group_type": "Active Comparator", 
                "description": "Metoprolol Tartrate 100 mg once a day"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, open-label, single & multiple-dose, three-sequence, three-period\n      crossover study to investigate the effect of sarpogrelate hydrochloride on the disposition\n      of metoprolol tartrate in healthy male volunteers"
        }, 
        "brief_title": "Sarpogrelate Drug Interaction", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hypertension", 
            "Peripheral Artery Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Peripheral Arterial Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "Eligibility for participation of this study will be determined from demographic information,\n      medical history, physical examination, electrocardiogram (ECG) and clinical laboratory tests\n      within 4 weeks before study drug administration. Subjects suitable for this study will be\n      admitted to the Clinical Trial Center of Ajou University Medical Center on the day before\n      dosing (Day -1).\n\n      On Day 1, Subjects will be dosed study drug (metoprolol tartrate 100 mg once a day only, or\n      metoprolol tartrate 100 mg once a day with sarpogrelate hydrochloride 100 mg three times a\n      day, sarpogrelate hydrochloride 100 mg three times a day pretreatment for three days and\n      metoprolol tartrate 100 mg once a day with sarpogrelate hydrochloride 100 mg three times a\n      day).\n\n      Pharmacokinetic samplings and blood pressure/pulse rate measurement will be done upto 12\n      hours after metoprolol tartrate 100 mg dosing.\n\n      After one week of washout period (Day 8), Subjects will be dosed study drug by crossover\n      manner, and pharmacokinetic samplings and blood pressure/pulse rate measurement will be done\n      upto 12 hours after metoprolol tartrate 100 mg dosing.\n\n      After one week of washout period (Day 15), Subjects will be dosed study drug by crossover\n      manner, and pharmacokinetic samplings and blood pressure/pulse rate measurement will be done\n      upto 12 hours after metoprolol tartrate 100 mg dosing."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects aged 20 - 45 years\n\n          -  With in 20% of ideal body weight, {Ideal body weight=[height(cm)-100]*0.9}\n\n          -  Agreement with written informed consent\n\n        Exclusion Criteria:\n\n          -  Clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic,\n             gastrointestinal disease or mental disorder (Past history or present)\n\n          -  Inadequate result of laboratory test (especially, AST/ALT > 1.25 x UNL, Total\n             bilirubin > 1.5 x UNL)\n\n          -  Positive reaction in the HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL test\n\n          -  Taking OTC(Over the counter)medicine including oriental medicine within 7 days\n\n          -  Clinically significant allergic disease (Except for mild allergic rhinitis and\n             dermatitis seems to be not need for medication)\n\n          -  Subject with known for hypersensitivity reaction to Metoprolol or Sarpogrelate\n\n          -  Previous whole blood donation within 60 days or component blood donation within 30\n             days\n\n          -  Previous participation of other trial within 90 days\n\n          -  Continued taking caffeine (caffeine > 5 cup/day), drinking (alcohol > 30 g/day) and\n             severe heavy smoker (cigarette > 1/2 pack per day)\n\n          -  An impossible one who participates in clinical trial by investigator's decision\n             including for reason of laboratory test result"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097511", 
            "org_study_id": "DDI-102"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sarpogrelate pretreatment and Metoprolol", 
                "description": "Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days", 
                "intervention_name": "Sarpogrelate pretreatment", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sarpogrelate pretreatment and Metoprolol", 
                    "Sarpogrelate and Metoprolol"
                ], 
                "description": "Sarpogrelate hydrochloride 100 mg three times a day", 
                "intervention_name": "Sarpogrelate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sarpogrelate pretreatment and Metoprolol", 
                    "Sarpogrelate and Metoprolol", 
                    "Metoprolol only"
                ], 
                "description": "Metoprolol Tartrate 100 mg once a day", 
                "intervention_name": "Metoprolol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metoprolol", 
                "Metoprolol succinate", 
                "Sarpogrelate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Drug-drug interaction", 
            "Pharmacokinetics", 
            "Pharmacodynamics"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "contact": {
                "email": "dooycho@ajou.ac.kr", 
                "last_name": "Doo-Yeoun Cho, MD", 
                "phone": "+82-31-219-4271"
            }, 
            "facility": {
                "address": {
                    "city": "Suwon", 
                    "country": "Korea, Republic of", 
                    "state": "Gyeonggi", 
                    "zip": "433-721"
                }, 
                "name": "Ajou University School of Medicine"
            }, 
            "investigator": {
                "last_name": "Doo-Yeoun Cho, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Open-label, Three-sequence, Three-period Crossover Study to Investigate The Effect of Anplag on the Disposition of Betaloc in Healthy Male Volunteers", 
        "overall_contact": {
            "email": "dooycho@ajou.ac.kr", 
            "last_name": "Doo-Yeoun Cho, MD", 
            "phone": "+82-31-219-4271"
        }, 
        "overall_official": {
            "affiliation": "Ajou University School of Medicine", 
            "last_name": "Doo-Yeoun Cho, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cmax (maximal plasma concentration) and AUC (area under the time-concentration curve) will be calculated from pharmacokinetic samplings", 
            "measure": "Plasma concentration of Metoprolol and metabolites", 
            "safety_issue": "No", 
            "time_frame": "upto 12 hours after Metoprolol Tartrate 100 mg dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097511"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ajou University School of Medicine", 
            "investigator_full_name": "Doo-Yeoun Cho", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Blood pressure and pulse rate measurement with Dash 5000 patient monitoring system (GE Healthcare, USA) at 0 (before Metoprolol Tartrate 100 mg dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12 hours after Metoprolol Tartrate 100 mg dosing", 
            "measure": "Blood pressure and pulse rate changes", 
            "safety_issue": "No", 
            "time_frame": "Upto 12 hours after Metoprolol Tartrate 100 mg dosing"
        }, 
        "source": "Ajou University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ajou University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}